Specify a stock or a cryptocurrency in the search bar to get a summary
Deltex Medical Group
DEMGDeltex Medical Group plc, together with its subsidiaries, manufactures, markets, and sells oesophageal doppler haemodynamic monitoring systems under the TrueVue name in the United Kingdom, the United States, and internationally. It offers oesophageal Doppler Probes that is used to guide fluid and drug interventions and haemodynamic monitoring; TrueVue Loops that plots aortic blood flow velocity and aortic blood pressure; High Definition Impedance Cardiography, a non-invasive cardiac function and fluid status monitoring system for awake patients; DoppLink, a patient interface cable that enhances signal processing; and PressureWave, a pulse contour analysis algorithm. The company also provides Deltex Medical Esophageal Doppler Simulator that enables clinicians to practice probe insertion, focusing, and waveform interpretation outside of a patient setting; and TrueVue monitor. Its products are used in sepsis; abdominal, laparoscopic, and spinal surgeries; cardiac, trauma, and transplant procedures; and post-operative acute kidney injury monitoring. Deltex Medical Group plc was incorporated in 2000 and is headquartered in Chichester, the United Kingdom. Address: Terminus Road, Chichester, United Kingdom, PO19 8TX
Analytics
WallStreet Target Price
618.06 GBXP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures DEMG
Dividend Analytics DEMG
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History DEMG
Stock Valuation DEMG
Financials DEMG
Results | 2019 | Dynamics |